Aligos Therapeutics Q2 net loss narrows on licensing revenue
ALGS•Analyst view
The average analyst rating on the shares is buy, with 8 strong buy or buy recommendations, no hold ratings, and no sell or strong sell ratings.
The median 12-month price target is $45.00, about 849.4% above the August 5 closing price of $4.74.
Outlook and cash runway
Aligos expects topline data from the Phase 2 B-SUPREME study in late Q3 2027.
The company said it expects cash and equivalents to fund operations through Q4 2026 and expects to receive a $3 million milestone payment in Q3 2026.
Q2 loss narrows on licensing revenue
Aligos Therapeutics' second-quarter net loss narrowed sharply from the prior year, as revenue included $25 million in upfront payments and $3 million in milestone payments from licensing deals.
The company reported a second-quarter loss per share of $0.14 and a net loss of .
